US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
*
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6150584A
(en)
*
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1690935A3
(en)
*
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
WO1996022380A2
(en)
*
|
1995-01-20 |
1996-07-25 |
Cell Genesys, Inc. |
Method to improve screening efficiency in fused cells
|
US6091001A
(en)
*
|
1995-03-29 |
2000-07-18 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6130364A
(en)
*
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6884622B1
(en)
|
1995-04-21 |
2005-04-26 |
Abgenix, Inc |
Method for preparing a mammalian cell deficient in HPRT
|
AU4376400A
(en)
*
|
1995-04-27 |
2000-11-30 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
CA2219361C
(en)
*
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
AU2008202860B9
(en)
*
|
1995-04-27 |
2012-03-29 |
Amgen Fremont Inc. |
Human Antibodies Derived From Immunized Xenomice
|
CA2219486A1
(en)
*
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
ES2283005T3
(es)
*
|
1995-07-21 |
2007-10-16 |
University Of Nebraska Board Of Regents |
Composiciones y procedimientos para catalizar la hidrolisis de gp 120 de hiv.
|
US6632976B1
(en)
|
1995-08-29 |
2003-10-14 |
Kirin Beer Kabushiki Kaisha |
Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
US6420140B1
(en)
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
EP2314625B1
(en)
*
|
1996-12-03 |
2014-05-07 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
ES2382488T3
(es)
|
1997-03-21 |
2012-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
KR20010022846A
(ko)
|
1997-08-15 |
2001-03-26 |
나가야마 오사무 |
항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
|
TWI255853B
(en)
|
1998-08-21 |
2006-06-01 |
Kirin Brewery |
Method for modifying chromosomes
|
EP1136548A4
(en)
|
1998-11-04 |
2002-09-25 |
Chugai Pharmaceutical Co Ltd |
NEW SERINE PROTEASES FROM THE TRYPSIN FAMILY
|
EP2112166B1
(en)
|
1998-12-23 |
2018-11-21 |
Pfizer Inc. |
Human monoclonal antibodies to ctla-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
EP1176198A4
(en)
|
1999-04-09 |
2002-10-30 |
Chugai Pharmaceutical Co Ltd |
FETAL GENES
|
ES2339843T3
(es)
|
1999-06-02 |
2010-05-26 |
Chugai Seiyaku Kabushiki Kaisha |
Proteina receptora de hematopoyetina novedosa, nr10.
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
JP4671570B2
(ja)
|
1999-08-23 |
2011-04-20 |
中外製薬株式会社 |
Hm1.24抗原の発現増強剤
|
KR100996759B1
(ko)
|
1999-08-24 |
2010-11-25 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
WO2001018200A1
(fr)
|
1999-09-06 |
2001-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Gene de type tsg
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
DE60042220D1
(de)
|
1999-09-21 |
2009-06-25 |
Chugai Pharmaceutical Co Ltd |
Verwendung vom transportergen oatp-c zur screening von testsubstanzen
|
PL354961A1
(en)
|
1999-10-01 |
2004-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
WO2001053484A1
(fr)
|
2000-01-24 |
2001-07-26 |
Haruo Sugiyama |
Proteine wtip interagissant avec wt1
|
TWI373343B
(en)
|
2000-02-10 |
2012-10-01 |
Abbott Gmbh & Co Kg |
Antibodies that bind human interleukin-18 and methods of making and using
|
US6653448B1
(en)
|
2000-03-29 |
2003-11-25 |
Curagen Corporation |
Wnt-7B-like polypeptides and nucleic acids encoding same
|
AU2001253339A1
(en)
*
|
2000-04-10 |
2001-10-23 |
American Biogenetic Sciences Inc. |
Human immunoglobulin-producing gnotobiotics
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
AU2001270266B2
(en)
|
2000-06-28 |
2004-10-21 |
Amgen Inc. |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
NZ525664A
(en)
*
|
2000-11-17 |
2008-08-29 |
Kirin Holdings Kk |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
MXPA03004793A
(es)
|
2000-11-30 |
2004-12-03 |
Medarex Inc |
Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
|
EP2339035A1
(en)
|
2000-12-07 |
2011-06-29 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
ES2344592T3
(es)
|
2001-01-05 |
2010-09-01 |
Pfizer Inc. |
Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
|
WO2002064159A1
(en)
|
2001-02-07 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for tumor in hematopoietic organs
|
EP1377165B1
(en)
|
2001-03-14 |
2009-07-01 |
Myriad Genetics, Inc. |
Tsg101-gag interaction and use thereof
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
EP1385864B1
(en)
|
2001-04-13 |
2010-06-09 |
Human Genome Sciences, Inc. |
Anti-VEGF-2 antibodies
|
CN100448992C
(zh)
|
2001-05-11 |
2009-01-07 |
麒麟医药株式会社 |
含人抗体λ轻链基因的人类人工染色体
|
CA2447114A1
(en)
|
2001-05-16 |
2002-11-21 |
Abgenix, Inc. |
Human antipneumococcal antibodies from non-human animals
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
DK1461442T3
(en)
|
2001-11-30 |
2017-12-04 |
Amgen Fremont Inc |
Transgenic animals with human Ig lambda light chain genes
|
WO2003057881A1
(fr)
|
2001-12-28 |
2003-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Procede de stabilisation d'une proteine
|
CN101721362B
(zh)
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
EP1501855A4
(en)
|
2002-03-21 |
2006-02-22 |
Sagres Discovery Inc |
NEW COMPOSITIONS AND METHODS FOR CANCER
|
AU2003220930A1
(en)
|
2002-03-29 |
2003-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Emthod of screening transporter inhibitor
|
CA2479927C
(en)
|
2002-03-29 |
2013-03-12 |
Schering Corporation |
Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化n端ペプチドに対する抗体
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
CN1652820A
(zh)
|
2002-04-12 |
2005-08-10 |
梅达雷克斯公司 |
使用ctla-4抗体的治疗方法
|
CA2488404C
(en)
|
2002-06-06 |
2012-11-27 |
Oncotherapy Science, Inc. |
Genes and polypeptides relating to human colon cancers
|
ES2361541T3
(es)
|
2002-06-06 |
2011-06-17 |
Oncotherapy Science, Inc. |
Genes y polipéptidos relacionados con cánceres de colon humanos.
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
ZA200500480B
(en)
|
2002-07-15 |
2006-10-25 |
Wyeth Corp |
Methods and compositions for modulating T helper (TH) cell development and function
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
US20060058511A1
(en)
|
2002-08-27 |
2006-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing protein solution preparation
|
NZ605429A
(en)
|
2002-09-06 |
2014-08-29 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
AU2003267124A1
(en)
|
2002-09-09 |
2004-03-29 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
JP5525118B2
(ja)
|
2002-09-11 |
2014-06-18 |
中外製薬株式会社 |
タンパク質精製方法
|
TW200413725A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancers
|
TW200413539A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Genes and polypeptides relating to prostate cancers
|
ATE492636T1
(de)
|
2002-10-22 |
2011-01-15 |
Eisai R&D Man Co Ltd |
Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
|
EP1559786A4
(en)
|
2002-10-30 |
2006-01-11 |
Chugai Pharmaceutical Co Ltd |
MEMBRANE PROTEINS DERIVED FROM MASTOCYTES
|
BR0315300A
(pt)
|
2002-11-08 |
2005-08-30 |
Hematech Llc |
Ungulados transgênicos tendo atividade de proteìna priÈnica reduzida e seus usos
|
EP2246363A1
(en)
|
2002-11-15 |
2010-11-03 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
EP1660535A2
(en)
|
2002-11-27 |
2006-05-31 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
DE60333228D1
(de)
|
2002-12-02 |
2010-08-12 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
WO2004058797A2
(en)
|
2002-12-16 |
2004-07-15 |
Medarex, Inc. |
Human monoclonal antibodies against interleukin 8 (il-8)
|
WO2004061108A1
(ja)
|
2002-12-29 |
2004-07-22 |
Toudai Tlo, Ltd. |
アディポネクチン受容体及びそれをコードする遺伝子
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
EP2058408A3
(en)
|
2003-02-14 |
2009-09-09 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
EP3000886A1
(en)
|
2003-03-19 |
2016-03-30 |
Amgen Fremont Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
ATE449842T1
(de)
|
2003-05-28 |
2009-12-15 |
Takeda Pharmaceutical |
Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
JPWO2005017155A1
(ja)
|
2003-06-18 |
2006-10-12 |
中外製薬株式会社 |
フコーストランスポーター
|
US7628986B2
(en)
|
2003-06-27 |
2009-12-08 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP2311468B1
(en)
|
2003-08-08 |
2014-01-15 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
ATE420660T1
(de)
|
2003-08-08 |
2009-01-15 |
Amgen Fremont Inc |
Antikörper gegen parath-hormon (pth) und ihre verwendungen
|
WO2005014854A1
(en)
|
2003-08-08 |
2005-02-17 |
Licentia, Ltd. |
Materials and methods for colorectal cancer screening, diagnosis, and therapy
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US7750123B2
(en)
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
CA2548185A1
(en)
|
2003-12-03 |
2005-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
Expression systems using mammalian .beta.-actin promoter
|
JP4898452B2
(ja)
|
2003-12-05 |
2012-03-14 |
マルチミューン ジーエムビーエイチ |
治療および診断用抗Hsp70抗体
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
EP1710255A4
(en)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
|
JP5422101B2
(ja)
|
2004-01-07 |
2014-02-19 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
M−csf特異的モノクローナル抗体およびその使用
|
CA2552523C
(en)
|
2004-01-09 |
2019-11-26 |
Pfizer Inc. |
Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
|
EP2418224A3
(en)
|
2004-03-19 |
2013-07-24 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
ATE496142T1
(de)
|
2004-03-23 |
2011-02-15 |
Oncotherapy Science Inc |
Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
US7420099B2
(en)
|
2004-04-22 |
2008-09-02 |
Kirin Holdings Kabushiki Kaisha |
Transgenic animals and uses thereof
|
EP1761784B1
(en)
|
2004-05-24 |
2016-10-26 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
DK2287195T3
(da)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
|
JP4011100B2
(ja)
|
2004-07-09 |
2007-11-21 |
中外製薬株式会社 |
抗グリピカン3抗体
|
AU2005264063B2
(en)
|
2004-07-16 |
2009-09-10 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
US20080199437A1
(en)
|
2004-07-22 |
2008-08-21 |
Eisai Co., Ltd. |
Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
|
CA2574881C
(en)
|
2004-08-04 |
2013-01-08 |
Amgen Inc. |
Antibodies to dkk-1
|
ATE497508T1
(de)
|
2004-10-01 |
2011-02-15 |
Max Planck Gesellschaft |
Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
AU2012200570A1
(en)
*
|
2004-10-22 |
2012-02-23 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
ES2679282T3
(es)
|
2004-10-22 |
2018-08-23 |
Revivicor Inc. |
Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
|
DE602005025525D1
(de)
|
2004-11-17 |
2011-02-03 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
ATE504602T1
(de)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
EP1829961A4
(en)
|
2004-12-22 |
2008-06-04 |
Chugai Pharmaceutical Co Ltd |
PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
|
US7566772B2
(en)
|
2005-01-26 |
2009-07-28 |
Amgen Fremont Inc. |
Antibodies against interleukin-1β
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
EP1856278A2
(en)
|
2005-02-10 |
2007-11-21 |
Oncotherapy Science, Inc. |
Method of diagnosing bladder cancer
|
JP2008532493A
(ja)
|
2005-02-14 |
2008-08-21 |
ワイス |
Il−17fとil−17rとの間の相互作用の特性解析
|
CA2596509A1
(en)
|
2005-02-14 |
2006-08-24 |
Wyeth |
Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
|
CA2597717C
(en)
|
2005-02-18 |
2014-10-21 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
TWI406870B
(zh)
|
2005-02-21 |
2013-09-01 |
Chugai Pharmaceutical Co Ltd |
A method of making a protein using hamster IGF-1
|
CA2600836A1
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
WO2006105448A2
(en)
|
2005-03-30 |
2006-10-05 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
EP1870459B1
(en)
|
2005-03-31 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
EP1910557A2
(en)
|
2005-04-07 |
2008-04-16 |
Chiron Corporation |
Cancer-related genes
|
ES2494921T3
(es)
|
2005-04-08 |
2014-09-16 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
MX2007013058A
(es)
|
2005-04-20 |
2008-02-22 |
Amgen Fremont Inc |
Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
|
BRPI0610248A2
(pt)
|
2005-04-25 |
2010-06-08 |
Pfizer |
anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos
|
EP1877444A2
(en)
|
2005-04-26 |
2008-01-16 |
Pfizer, Inc. |
P-cadherin antibodies
|
PL1899364T3
(pl)
|
2005-05-17 |
2020-08-24 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
NZ596992A
(en)
|
2005-06-30 |
2013-07-26 |
Abbott Lab |
Il-12/p40 binding proteins
|
EP2336780A1
(en)
|
2005-07-27 |
2011-06-22 |
Oncotherapy Science, Inc. |
Genes and polypeptides relating to prostate cancers
|
US8652469B2
(en)
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
KR20080039999A
(ko)
|
2005-08-18 |
2008-05-07 |
젠맵 에이/에스 |
Cd4 결합 펩티드 및 방사선을 이용한 치료
|
BRPI0615026A8
(pt)
|
2005-08-19 |
2018-03-06 |
Abbott Lab |
imunoglobulina de domínio variável duplo e seus usos
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
PL1933871T3
(pl)
|
2005-09-07 |
2013-09-30 |
Amgen Fremont Inc |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do recepora aktywiny-1
|
ES2400520T3
(es)
|
2005-09-29 |
2013-04-10 |
Eisai R&D Management Co., Ltd. |
Molécula de adhesión a las células T y anticuerpo contra la molécula
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
BRPI0617378B8
(pt)
|
2005-10-14 |
2022-09-20 |
Chugai Pharmaceutical Co Ltd |
Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
|
JP5191235B2
(ja)
|
2005-10-21 |
2013-05-08 |
中外製薬株式会社 |
心疾患治療剤
|
AU2006315580A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
KR101906161B1
(ko)
|
2005-11-30 |
2018-10-11 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
NZ568016A
(en)
|
2005-12-07 |
2011-12-22 |
Medarex Inc |
CTLA-4 antibody dosage escalation regimens
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
WO2007074880A1
(ja)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
HUE028179T2
(en)
|
2006-01-12 |
2016-12-28 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and their use
|
AU2007219159B8
(en)
|
2006-01-25 |
2012-06-28 |
Roger Kingdon Craig |
Generation of heavy-chain only antibodies in transgenic animals
|
WO2007086490A1
(ja)
|
2006-01-27 |
2007-08-02 |
Keio University |
脈絡膜血管新生を伴う疾患の治療剤
|
EP1982181B1
(en)
|
2006-02-06 |
2010-12-15 |
Rhode Island Hospital |
Gpr30 estrogen receptor in breast cancers
|
EP2010569A4
(en)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
FOR GASTRIN SPECIFIC HUMAN ANTIBODIES, MATERIALS AND METHODS
|
EP3056568B1
(en)
|
2006-03-31 |
2021-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
JP2009532033A
(ja)
|
2006-03-31 |
2009-09-10 |
ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド |
細胞の化学感受性を定量する方法
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
CA2648846A1
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2012827A2
(en)
|
2006-04-13 |
2009-01-14 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancer
|
WO2007119796A1
(ja)
|
2006-04-14 |
2007-10-25 |
Medical And Biological Laboratories Co., Ltd. |
エフェクター機能を有するポリペプチド変異体
|
EP2019684A4
(en)
|
2006-04-20 |
2009-08-26 |
Jackson H M Found Military Med |
METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN PROTEIN TYPE 1
|
JP5311303B2
(ja)
|
2006-04-25 |
2013-10-09 |
国立大学法人 東京大学 |
アルツハイマー病および癌の治療薬
|
KR20150091545A
(ko)
|
2006-06-08 |
2015-08-11 |
추가이 세이야쿠 가부시키가이샤 |
염증성 질환의 예방 또는 치료제
|
JPWO2007145227A1
(ja)
|
2006-06-14 |
2009-11-05 |
中外製薬株式会社 |
造血幹細胞増加促進剤
|
US20100159450A1
(en)
|
2006-06-23 |
2010-06-24 |
Susanne Wagner |
Dpyd gene variants and use thereof
|
JPWO2008007755A1
(ja)
|
2006-07-13 |
2009-12-10 |
中外製薬株式会社 |
細胞死誘導剤
|
JP5175729B2
(ja)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
腎疾患治療剤
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
CN103524619B
(zh)
|
2006-08-03 |
2016-10-05 |
阿斯利康(瑞典)有限公司 |
针对αVβ6的抗体及其应用
|
SI2511301T1
(en)
|
2006-08-04 |
2018-05-31 |
MedImmune Limited, |
Human antibodies to ERBB 2
|
RU2009107707A
(ru)
|
2006-08-04 |
2010-09-10 |
Новартис АГ (CH) |
СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
|
AU2007285217B2
(en)
|
2006-08-14 |
2013-02-07 |
Forerunner Pharma Research Co., Ltd |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
MX2009001829A
(es)
|
2006-08-18 |
2009-05-28 |
Novartis Ag |
Anticuerpo especifico prlr y sus usos.
|
SG174053A1
(en)
|
2006-09-01 |
2011-09-29 |
Therapeutic Human Polyclonals Inc |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
KR101676269B1
(ko)
|
2006-09-08 |
2016-11-15 |
애브비 바하마스 리미티드 |
인터루킨-13 결합 단백질
|
EP2083017A4
(en)
|
2006-09-14 |
2011-01-12 |
Med & Biological Lab Co Ltd |
ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
KR101474227B1
(ko)
|
2006-10-02 |
2014-12-18 |
리제너론 파아마슈티컬스, 인크. |
사람 il-4 수용체에 대한 고친화성 사람 항체
|
EP2083852B1
(en)
|
2006-10-04 |
2014-12-10 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
NZ601022A
(en)
|
2006-10-12 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
CA2666809A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
|
AU2007311957A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
CA2668295A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
US20100111852A1
(en)
|
2006-12-14 |
2010-05-06 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
KR20090114388A
(ko)
|
2007-01-05 |
2009-11-03 |
유니버시티 오브 취리히 |
질환 특이적 결합 분자 및 표적을 제공하는 방법
|
EP2123676A4
(en)
|
2007-01-05 |
2011-01-05 |
Univ Tokyo |
DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
|
KR20150038227A
(ko)
|
2007-01-16 |
2015-04-08 |
애브비 인코포레이티드 |
건선의 치료방법
|
BRPI0806812B8
(pt)
|
2007-01-23 |
2021-09-14 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
|
CA2677996C
(en)
|
2007-02-09 |
2018-06-12 |
Eisai R&D Management Co., Ltd. |
Gaba neuron progenitor cell marker 65b13
|
EP2123299A4
(en)
|
2007-02-15 |
2011-10-05 |
Univ Kyushu Nat Univ Corp |
THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
CN101951953A
(zh)
|
2007-02-27 |
2011-01-19 |
株式会社未来创药研究所 |
含抗grp78抗体作为有效成分的药物组合物
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
PL2457928T3
(pl)
|
2007-03-13 |
2017-10-31 |
Univ Zuerich |
Monoklonalne ludzkie przeciwciało swoiste względem nowotworu
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
SI2125894T1
(sl)
|
2007-03-22 |
2019-05-31 |
Biogen Ma Inc. |
Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
|
EP2142214A4
(en)
|
2007-04-02 |
2012-03-21 |
Amgen Fremont Inc |
ANTI-IGE ANTIBODIES
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
PT2336329E
(pt)
|
2007-06-01 |
2012-12-24 |
Omt Inc |
Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
|
JP5469456B2
(ja)
|
2007-06-25 |
2014-04-16 |
中外製薬株式会社 |
ADCC活性又はCDC活性を有する抗Prominin−1抗体
|
WO2009008414A1
(ja)
|
2007-07-10 |
2009-01-15 |
Shionogi & Co., Ltd. |
Mmp13に対する中和活性を有するモノクローナル抗体
|
EP3246045A1
(en)
|
2007-07-26 |
2017-11-22 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
CA2695237A1
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
EP2192179B9
(en)
|
2007-08-20 |
2017-11-15 |
Oncotherapy Science, Inc. |
Cdh3 peptide and medicinal agent comprising the same
|
AU2008290049B2
(en)
|
2007-08-20 |
2013-08-29 |
Oncotherapy Science, Inc. |
FOXM1 peptide and medicinal agent comprising the same
|
PT2186889E
(pt)
|
2007-08-20 |
2015-06-17 |
Oncotherapy Science Inc |
Péptido cdca1 e agente farmacêutico que o compreende
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
EP2527369A3
(en)
|
2007-09-13 |
2012-12-19 |
University Of Zurich Prorektorat Forschung |
Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
WO2009040134A1
(en)
|
2007-09-26 |
2009-04-02 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
DK2196541T3
(da)
|
2007-09-28 |
2012-11-26 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3-antistof med forbedret kinetik i plasmaet
|
WO2009044774A1
(ja)
|
2007-10-02 |
2009-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
インターロイキン6受容体阻害剤を有効成分とする移植片対宿主病治療剤
|
CN101802192A
(zh)
|
2007-10-15 |
2010-08-11 |
中外制药株式会社 |
抗体的制备方法
|
JPWO2009051220A1
(ja)
|
2007-10-19 |
2011-03-03 |
イムナス・ファーマ株式会社 |
Aβオリゴマーに特異的に結合する抗体およびその利用
|
JP5620106B2
(ja)
|
2007-10-24 |
2014-11-05 |
株式会社糖鎖工学研究所 |
増強されたエフェクター機能を有するポリペプチド
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
DK2220121T3
(en)
|
2007-11-12 |
2015-12-07 |
U3 Pharma Gmbh |
AXL antibodies
|
CN102112492B
(zh)
|
2007-11-14 |
2015-02-25 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
PE20091024A1
(es)
|
2007-11-15 |
2009-08-12 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen a anexelekto y sus usos
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
TW201634479A
(zh)
|
2007-12-05 |
2016-10-01 |
Chugai Pharmaceutical Co Ltd |
抗nr10抗體及其應用
|
MY185647A
(en)
|
2007-12-05 |
2021-05-27 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for pruritus
|
WO2009079259A2
(en)
|
2007-12-06 |
2009-06-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
EP2851373A1
(en)
|
2007-12-20 |
2015-03-25 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
EP2235058A2
(en)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
WO2009086514A1
(en)
|
2007-12-28 |
2009-07-09 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
US9274119B2
(en)
|
2008-01-11 |
2016-03-01 |
The University Of Tokyo |
Anti-CLDN6 antibody
|
AU2009206306B2
(en)
|
2008-01-25 |
2013-06-06 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
PL2246427T3
(pl)
|
2008-02-08 |
2017-06-30 |
Immunas Pharma, Inc. |
Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
AU2009225797A1
(en)
|
2008-03-18 |
2009-09-24 |
Abbvie Inc. |
Methods for treating psoriasis
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
CA2721052C
(en)
|
2008-04-11 |
2023-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
ES2487846T3
(es)
|
2008-05-01 |
2014-08-25 |
Amgen, Inc. |
Anticuerpos anti-hepcindina y métodos de uso
|
MX343624B
(es)
|
2008-05-09 |
2016-11-14 |
Abbott Laboratories * |
Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
WO2009149185A2
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
TWI528973B
(zh)
|
2008-06-05 |
2016-04-11 |
Chugai Pharmaceutical Co Ltd |
Nerve infiltration inhibitor
|
CN102124030B
(zh)
|
2008-06-20 |
2015-06-17 |
国立大学法人冈山大学 |
抗氧化LDL/β2GPI复合物的抗体及其用途
|
WO2010006060A2
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
EP2810654A1
(en)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin E2 binding proteins and uses thereof
|
SG10201701323TA
(en)
|
2008-08-18 |
2017-04-27 |
Amgen Fremont Inc |
Antibodies to ccr2
|
EP4071169A2
(en)
|
2008-08-25 |
2022-10-12 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
NZ592308A
(en)
|
2008-09-30 |
2012-11-30 |
Ablexis Llc |
Non-human mammals for the production of chimeric antibodies
|
KR20110069144A
(ko)
|
2008-10-09 |
2011-06-22 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
EP2348827B1
(en)
|
2008-10-27 |
2015-07-01 |
Revivicor, Inc. |
Immunocompromised ungulates
|
PL2894165T3
(pl)
|
2008-11-10 |
2023-04-17 |
Alexion Pharmaceuticals, Inc. |
Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
|
SI2370466T1
(sl)
|
2008-12-19 |
2015-11-30 |
Biogen International Neuroscience Gmbh |
Človeška avtoprotitelesa proti alfa-sinukleinu
|
JP5523346B2
(ja)
|
2008-12-22 |
2014-06-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Neph3を用いた膵臓前駆細胞の取得方法
|
EP2388320B1
(en)
|
2008-12-22 |
2017-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hs6st2 antibodies and uses thereof
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
JP6009733B2
(ja)
|
2008-12-25 |
2016-10-19 |
国立大学法人 東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
US20120014870A1
(en)
|
2008-12-26 |
2012-01-19 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
|
US8309530B2
(en)
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
WO2010102251A2
(en)
|
2009-03-05 |
2010-09-10 |
Abbott Laboratories |
Il-17 binding proteins
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
JP2012521360A
(ja)
|
2009-03-20 |
2012-09-13 |
アムジエン・インコーポレーテツド |
Kv1.3の選択的かつ強力なペプチド阻害剤
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
EP2419447B1
(en)
|
2009-04-17 |
2017-08-23 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
CN102753579A
(zh)
|
2009-05-01 |
2012-10-24 |
国立大学法人东京大学 |
抗钙粘着蛋白抗体
|
WO2010129600A2
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
TWI560197B
(en)
|
2009-05-05 |
2016-12-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
MX2011011729A
(es)
|
2009-05-05 |
2012-04-10 |
Novimmune Sa |
Anticuerpo anti il-17f y metodos de uso de los mismos.
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
SG178190A1
(en)
|
2009-07-31 |
2012-03-29 |
Shin Maeda |
Cancer metastasis inhibitor
|
EP2287336A1
(fr)
|
2009-07-31 |
2011-02-23 |
Exhonit Therapeutics SA |
Procédés et méthodes de diagnostic de la maladie d'Alzheimer
|
CA2770237A1
(en)
|
2009-08-05 |
2011-02-10 |
Nexigen Gmbh |
Human hcv-interacting proteins and methods of use
|
DK2462161T3
(en)
|
2009-08-06 |
2017-06-06 |
Immunas Pharma Inc |
Antibodies specifically binding to A-beta oligomers and their use
|
US8613924B2
(en)
|
2009-08-06 |
2013-12-24 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to A beta oligomers and use thereof
|
CN102574917A
(zh)
|
2009-08-17 |
2012-07-11 |
株式会社未来创药研究所 |
含有抗hb-egf抗体作为有效成分的药物组合物
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
JP6109571B2
(ja)
|
2009-08-28 |
2017-04-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
複数種のCCケモカインと結合するantikine抗体
|
CN105131112A
(zh)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
治疗用dll4结合蛋白
|
CA2772628A1
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
RU2012114854A
(ru)
|
2009-09-14 |
2013-10-27 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
PE20121531A1
(es)
|
2009-10-15 |
2012-12-22 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
EP2496604B1
(en)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Canine anti-cd20 antibodies
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
PT2719708T
(pt)
|
2009-11-13 |
2018-01-16 |
Daiichi Sankyo Europe Gmbh |
Material e métodos para tratamento ou prevenção de doenças associadas a her-3
|
JP2013511279A
(ja)
|
2009-11-20 |
2013-04-04 |
アムジエン・インコーポレーテツド |
抗Orai1抗原結合蛋白及びその使用
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
US9420770B2
(en)
|
2009-12-01 |
2016-08-23 |
Indiana University Research & Technology Corporation |
Methods of modulating thrombocytopenia and modified transgenic pigs
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
CA2786692A1
(en)
|
2010-01-11 |
2011-07-14 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
WO2011092989A1
(ja)
|
2010-01-29 |
2011-08-04 |
東レ株式会社 |
ポリ乳酸系樹脂シート
|
PT2530091T
(pt)
|
2010-01-29 |
2018-05-17 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-dll3
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
ES2547142T5
(es)
|
2010-02-08 |
2021-12-09 |
Regeneron Pharma |
Cadena ligera común de ratón
|
KR101900110B1
(ko)
|
2010-02-10 |
2018-09-18 |
후지필름 알아이 파르마 가부시키가이샤 |
방사성 금속 표지 항카드헤린 항체
|
EP2536761B1
(en)
|
2010-02-19 |
2017-09-20 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
US20120321557A1
(en)
|
2010-02-26 |
2012-12-20 |
Forerunner Pharma Research Co., Ltd. |
Anti-icam3 antibody and use thereof
|
MX348312B
(es)
|
2010-03-02 |
2017-06-06 |
Abbvie Inc |
Proteínas terapéuticas de enlace dll4.
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
NZ601171A
(en)
|
2010-03-31 |
2014-11-28 |
Ablexis Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
JP2013523184A
(ja)
|
2010-04-15 |
2013-06-17 |
アムジエン・インコーポレーテツド |
ヒトFGF受容体およびβ−KLOTHO結合性タンパク質
|
NZ603226A
(en)
|
2010-04-30 |
2015-02-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
MY161302A
(en)
|
2010-05-14 |
2017-04-14 |
Abbvie Inc |
IL-1 binding proteins
|
EP2578231B1
(en)
|
2010-05-28 |
2022-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
US20130149302A1
(en)
|
2010-05-28 |
2013-06-13 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for pancreatic cancer
|
EP2575882B1
(en)
|
2010-06-02 |
2017-11-01 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
CN103249432A
(zh)
|
2010-06-22 |
2013-08-14 |
科罗拉多大学董事会,法人团体 |
补体成分3的C3d片段的抗体
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP2013540694A
(ja)
|
2010-08-06 |
2013-11-07 |
ウー3・フアルマ・ゲー・エム・ベー・ハー |
Her3結合剤の前立腺治療における使用
|
CN103314296A
(zh)
|
2010-08-10 |
2013-09-18 |
安姆根有限公司 |
用于检测针对靶抗体的中和抗体的双功能体外靶结合测定
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
HRP20220405T1
(hr)
|
2010-08-19 |
2022-05-27 |
Zoetis Belgium S.A. |
Protutijela protiv ngf i njihova upotreba
|
EP2608803A4
(en)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
EP2609431B1
(en)
|
2010-08-27 |
2017-05-10 |
University of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
PT2616090T
(pt)
|
2010-09-17 |
2023-10-16 |
Takeda Pharmaceuticals Co |
Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
|
KR20130110169A
(ko)
|
2010-09-22 |
2013-10-08 |
암젠 인크 |
담체 면역글로뷸린 및 이것의 용도
|
LT2627672T
(lt)
|
2010-10-11 |
2018-12-10 |
Biogen International Neuroscience Gmbh |
Žmogaus antikūnai prieš tau baltymą
|
EP2632481A1
(en)
|
2010-10-25 |
2013-09-04 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
EP3838922A1
(en)
|
2010-10-27 |
2021-06-23 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
SI2634194T1
(sl)
|
2010-10-29 |
2018-11-30 |
Perseus Proteomics Inc. |
Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
|
SI2644698T1
(en)
|
2010-11-17 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
MULTISPECIFIC ANTIGEN-TUBULAR MOLECULAR, WITH AN ALTERNATIVE FUNCTION TO THE FACTOR OF BLOOD VIOLATION VIII
|
PT2647707T
(pt)
|
2010-11-30 |
2018-11-15 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de toxicidade
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
US9283271B2
(en)
|
2010-12-17 |
2016-03-15 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
US8853365B2
(en)
|
2010-12-21 |
2014-10-07 |
Abbvie Inc. |
Dual variable domain immunnoglobulins and uses thereof
|
CN108939067A
(zh)
|
2010-12-21 |
2018-12-07 |
瑟莱克斯制药公司 |
抗p-选择素抗体及其使用和鉴定方法
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
EP3961214A1
(en)
|
2010-12-31 |
2022-03-02 |
BioAtla, Inc. |
Comprehensive monoclonal antibody generation
|
WO2012099983A1
(en)
|
2011-01-18 |
2012-07-26 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
TW201244737A
(en)
|
2011-02-03 |
2012-11-16 |
Alexion Pharma Inc |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
EP2678026B1
(en)
|
2011-02-21 |
2016-05-18 |
The University of Zurich |
Ankyrin g for use in the treatment of neurodegenerative disorders
|
SG192945A1
(en)
|
2011-02-25 |
2013-09-30 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc antibody
|
JP2014509588A
(ja)
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
EP2500073A1
(en)
|
2011-03-17 |
2012-09-19 |
ChromaCon AG |
Method for identification and purification of multi-specific polypeptides
|
US9555108B2
(en)
|
2011-03-24 |
2017-01-31 |
Texas Tech University System |
TCR mimic antibodies as vascular targeting tools
|
DK2698431T3
(da)
|
2011-03-30 |
2020-11-30 |
Chugai Pharmaceutical Co Ltd |
Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
|
WO2012138774A2
(en)
|
2011-04-04 |
2012-10-11 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
JP6104794B2
(ja)
|
2011-04-18 |
2017-03-29 |
国立大学法人 東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
EP2710037B1
(en)
|
2011-05-19 |
2019-07-31 |
The Regents of The University of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
ES2894398T3
(es)
|
2011-06-03 |
2022-02-14 |
Xoma Technology Ltd |
Anticuerpos específicos para TGF-beta
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
MX2014000531A
(es)
|
2011-07-13 |
2014-12-05 |
Abbvie Inc |
Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
|
EP2735315B1
(en)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Stable protein-containing preparation containing argininamide or valinamide
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
EP2739652B1
(en)
|
2011-08-04 |
2017-04-05 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
IL297371A
(en)
|
2011-08-05 |
2022-12-01 |
Regeneron Pharma |
Humanized mice possess a universal light chain
|
EP2749572A4
(en)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
|
US10018630B2
(en)
|
2011-09-07 |
2018-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
AU2012311286B2
(en)
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
KR102239138B1
(ko)
|
2011-09-30 |
2021-04-12 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
MX366269B
(es)
|
2011-09-30 |
2019-07-04 |
Chugai Pharmaceutical Co Ltd |
Biblioteca de moleculas de union dependientes de la concentracion ionica.
|
ES2619707T3
(es)
|
2011-09-30 |
2017-06-26 |
Dana-Farber Cancer Institute, Inc. |
Péptidos terapéuticos
|
CA3186128A1
(en)
|
2011-09-30 |
2013-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
|
EP2764118A1
(en)
|
2011-10-05 |
2014-08-13 |
University of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
CN109456932A
(zh)
|
2011-10-17 |
2019-03-12 |
米纳瓦生物技术公司 |
用于干细胞增殖和诱导的培养基
|
DK2768851T3
(en)
|
2011-10-21 |
2017-09-18 |
Augurex Life Sciences Corp |
ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
KR20140084253A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Tnf에 대한 면역결합제
|
EP3603671A3
(en)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
JP2015500205A
(ja)
|
2011-11-16 |
2015-01-05 |
アムジエン・インコーポレーテツド |
上皮成長因子欠失変異体viii関連障害の治療方法
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
CA2858572C
(en)
|
2011-12-08 |
2023-01-17 |
Amgen Inc. |
Human lcat antigen binding proteins and their use in therapy
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791173B1
(en)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
WO2013093122A2
(en)
|
2011-12-23 |
2013-06-27 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CA2861695C
(en)
|
2011-12-28 |
2021-03-30 |
Immunoqure Ag |
Method of isolating human antibodies
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
|
CN107880124B
(zh)
|
2012-01-27 |
2021-08-13 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗与神经突变性相关的疾病的组合物和方法
|
MX360772B
(es)
|
2012-02-06 |
2018-11-15 |
Inhibrx Inc |
Anticuerpos cd47 y metodos de uso de los mismos.
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
AU2013222188A1
(en)
|
2012-02-22 |
2014-09-11 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
RU2736349C2
(ru)
|
2012-02-24 |
2020-11-16 |
Чугаи Сейяку Кабусики Кайся |
АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FcγRIIB
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
KR20140134672A
(ko)
|
2012-03-16 |
2014-11-24 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-의존성 결합 특성을 나타내는 항원-결합 단백질을 생성하는 마우스
|
HUE037659T2
(hu)
|
2012-03-16 |
2018-09-28 |
Regeneron Pharma |
Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
|
NZ629077A
(en)
|
2012-03-16 |
2015-12-24 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
DK2831117T3
(en)
|
2012-03-29 |
2017-12-18 |
Novimmune Sa |
ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF
|
EP2832856A4
(en)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
ANTI-LAMP5 ANTIBODIES AND USE THEREOF
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
CA2869704A1
(en)
|
2012-04-04 |
2013-10-10 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-cdh3 (pcadherin) antibody
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
JP6272299B2
(ja)
|
2012-04-20 |
2018-01-31 |
メルス ナムローゼ フェンノートシャップ |
Ig様分子を生産する方法、Ig様分子の混合物、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
PT2841456T
(pt)
|
2012-04-27 |
2018-10-19 |
Novo Nordisk As |
Proteinas de ligação ao antigénio do ligando de cd30 humano
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
JP6411329B2
(ja)
|
2012-05-04 |
2018-10-24 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
親和性成熟抗ccr4ヒト化モノクローナル抗体および使用法
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
JPWO2013180201A1
(ja)
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
CN104364264B
(zh)
|
2012-06-06 |
2018-07-24 |
硕腾服务有限责任公司 |
犬源化抗ngf抗体和其方法
|
EP2862875B1
(en)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
MX2014016038A
(es)
|
2012-06-22 |
2015-08-14 |
Cytomx Therapeutics Inc |
Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
|
EP2876160B1
(en)
|
2012-07-06 |
2020-05-13 |
Kyoto Prefectural Public University Corporation |
Differentiation marker for and differentiation control for ocular cells
|
TW201402608A
(zh)
|
2012-07-12 |
2014-01-16 |
Abbvie Inc |
Il-1結合蛋白質
|
TWI766493B
(zh)
|
2012-08-24 |
2022-06-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
US9561266B2
(en)
|
2012-08-31 |
2017-02-07 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
WO2014039675A2
(en)
|
2012-09-05 |
2014-03-13 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
CA2885230C
(en)
|
2012-09-19 |
2021-08-03 |
Anthony Letai |
Dynamic bh3 profiling
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
US10689705B2
(en)
|
2012-09-27 |
2020-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR3 fusion gene and pharmaceutical drug targeting same
|
BR112015006634B1
(pt)
|
2012-09-28 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Método e kit para avaliação de reação de coagulação sanguínea
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
EP2918603B1
(en)
|
2012-11-08 |
2018-08-29 |
University of Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
US11059910B2
(en)
|
2012-12-03 |
2021-07-13 |
Novimmune Sa |
Anti-CD47 antibodies and methods of use thereof
|
US20160000893A1
(en)
|
2012-12-13 |
2016-01-07 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
AU2013361107B2
(en)
|
2012-12-21 |
2018-08-23 |
Biogen International Neuroscience Gmbh |
Human anti-tau antibodies
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
CA2896824A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
EP4137518A1
(en)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
MX2015012824A
(es)
|
2013-03-14 |
2016-06-24 |
Abbott Lab |
Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
|
CN113549148A
(zh)
|
2013-03-14 |
2021-10-26 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
WO2014153056A2
(en)
|
2013-03-14 |
2014-09-25 |
Parkash Gill |
Cancer treatment using antibodies that bing cell surface grp78
|
EP2968526A4
(en)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
ANTIGEN-ANTIBODY COMBINATION ASSAY OF HEPATITIS C VIRUS AND METHODS AND COMPOSITIONS FOR USE THEREWITH
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
PL2970449T3
(pl)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
MX2015011075A
(es)
|
2013-03-15 |
2015-10-29 |
Dana Farber Cancer Inst Inc |
Peptidos terapeuticos.
|
TW201902931A
(zh)
|
2013-03-15 |
2019-01-16 |
美商安美基公司 |
人類pac1抗體
|
BR112015021341B1
(pt)
|
2013-03-15 |
2023-03-28 |
Dana-Farber Cancer Institute Inc. |
Anticorpos monoclonais humanizados isolados neutralizantes de flavivírus e usos terapêuticos dos mesmos
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
CA2907184C
(en)
|
2013-03-15 |
2022-12-06 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
TWI636062B
(zh)
|
2013-04-02 |
2018-09-21 |
中外製藥股份有限公司 |
Fc region variant
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
US9863953B2
(en)
|
2013-05-16 |
2018-01-09 |
Kyoto University |
Method for determining prognosis of cancer
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
AU2014299916A1
(en)
|
2013-06-24 |
2015-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
|
EP3013422A1
(en)
|
2013-06-28 |
2016-05-04 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
CN112358548A
(zh)
|
2013-07-03 |
2021-02-12 |
因美诺克股份公司 |
人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
|
EP2820947A1
(en)
|
2013-07-05 |
2015-01-07 |
B Cell Design |
Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015042249A1
(en)
|
2013-09-19 |
2015-03-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
TWI673063B
(zh)
|
2013-09-20 |
2019-10-01 |
日商中外製藥股份有限公司 |
抗蛋白c抗體之出血性疾病的治療
|
MX2016003616A
(es)
|
2013-09-27 |
2016-07-21 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir heteromultimeros de polipeptidos.
|
CN105683365A
(zh)
|
2013-10-01 |
2016-06-15 |
科马布有限公司 |
动物模型及治疗分子
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US20160280787A1
(en)
|
2013-11-11 |
2016-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
KR20220142539A
(ko)
|
2013-12-04 |
2022-10-21 |
추가이 세이야쿠 가부시키가이샤 |
화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
EP3581179A1
(en)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Fgfr gatekeeper mutant gene and drug targeting same
|
CN106029682B
(zh)
|
2013-12-27 |
2021-04-13 |
中外制药株式会社 |
等电点低的抗体的纯化方法
|
CN103865920B
(zh)
*
|
2013-12-31 |
2016-06-01 |
广州达恩基因科技有限公司 |
胚胎干细胞特有小分子多肽es61编码基因的克隆方法
|
EP3092007A4
(en)
*
|
2014-01-10 |
2017-06-07 |
Allermabs Co. Ltd. |
Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
WO2015121383A1
(en)
|
2014-02-12 |
2015-08-20 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
EP3119804A2
(en)
|
2014-03-19 |
2017-01-25 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
JP6636498B2
(ja)
|
2014-03-21 |
2020-01-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
単一ドメイン結合タンパク質を作る非ヒト動物
|
WO2015150900A2
(en)
|
2014-03-31 |
2015-10-08 |
Debiopharm International Sa |
Fgfr fusions
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
AU2015254596B2
(en)
|
2014-04-30 |
2020-10-22 |
Klinikum Rechts Der Isar Der Technischen Universitat Munchen |
Diagnosis of multiple sclerosis
|
CA2949237C
(en)
|
2014-05-16 |
2022-08-23 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
US20170198054A1
(en)
|
2014-05-21 |
2017-07-13 |
Dana-Farber Cancer Institute |
Methods for treating cancer with anti bip or anti mica antibodies
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
CN105315375B
(zh)
|
2014-07-17 |
2021-04-23 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
EP3174903B1
(en)
|
2014-07-31 |
2024-04-10 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibody construct with enhanced tissue distribution
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
US20170362304A1
(en)
|
2014-08-20 |
2017-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
TW201620938A
(zh)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CN108064248B
(zh)
|
2014-09-30 |
2022-03-15 |
生物控股有限公司 |
人源抗二肽重复(dpr)抗体
|
MX2017004311A
(es)
|
2014-10-03 |
2017-12-07 |
Dana Farber Cancer Inst Inc |
Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
|
EP3699196A1
(en)
|
2014-10-06 |
2020-08-26 |
Dana Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
US10202616B2
(en)
|
2014-10-15 |
2019-02-12 |
Amgen Inc. |
Promoter and regulatory elements for improved expression of heterologous genes in host cells
|
CN107406503B
(zh)
|
2014-11-18 |
2021-07-16 |
詹森药业有限公司 |
Cd47抗体、方法和用途
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
EP3034620A1
(en)
|
2014-12-17 |
2016-06-22 |
Diaxonhit |
Compositions and methods for diagnosing thyroid cancer
|
FR3030758A1
(fr)
|
2014-12-19 |
2016-06-24 |
Inst Nat De La Rech Agronomique (Inra) |
Marqueurs diagnostiques de la maladie de crohn
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
RU2730590C2
(ru)
|
2015-02-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Композиция для лечения заболеваний, связанных с ил-6
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
JP6726676B2
(ja)
|
2015-03-16 |
2020-07-22 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー)Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH) |
Hbv感染および関連症状を治療するための三重特異的結合分子
|
EP3271397B1
(en)
|
2015-03-18 |
2021-03-03 |
The Johns Hopkins University |
Inhibitory monoclonal antibody targeting potassium channel kcnk9
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016161410A2
(en)
|
2015-04-03 |
2016-10-06 |
Xoma Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
JP6960856B2
(ja)
|
2015-04-08 |
2021-11-05 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ヒト化インフルエンザモノクローナル抗体およびその使用方法
|
CN107454906B
(zh)
|
2015-04-17 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
使用凝固因子和多特异性抗体的联合治疗
|
MX2017013348A
(es)
|
2015-04-17 |
2018-08-01 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
US20180120297A1
(en)
|
2015-04-27 |
2018-05-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for assessing toxicity using dynamic bh3 profiling
|
KR102451786B1
(ko)
|
2015-04-28 |
2022-10-05 |
미쓰비시 타나베 파마 코퍼레이션 |
RGMa 결합 단백질 및 그 사용
|
JP6956639B2
(ja)
|
2015-05-01 |
2021-11-02 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
抗ccr4抗体を用いてサイトカイン発現を媒介する方法
|
ES2921350T3
(es)
|
2015-05-18 |
2022-08-24 |
Sumitomo Pharma Oncology Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
FR3036287A1
(fr)
|
2015-05-19 |
2016-11-25 |
Univ Bordeaux |
Traitement et detection des trypanosomes
|
SI3303395T1
(sl)
|
2015-05-29 |
2020-03-31 |
Abbvie Inc. |
Protitelesa proti CD40 in njihove uporabe
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
CA2994841A1
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
CN113372443A
(zh)
|
2015-09-18 |
2021-09-10 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
MX2018004041A
(es)
|
2015-10-01 |
2018-11-09 |
Amgen Inc |
Tratamiento de trastornos de acidos biliares.
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3375445A4
(en)
|
2015-11-30 |
2019-08-07 |
Xie, Yanhui |
USE OF AKT2 IN THE DIAGNOSIS AND TREATMENT OF A TUMOR
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
PE20181327A1
(es)
|
2015-12-23 |
2018-08-20 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
JP6954842B2
(ja)
|
2015-12-25 |
2021-10-27 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
BR112018015415A2
(pt)
|
2016-02-03 |
2018-12-18 |
Amgen Res Munich Gmbh |
célula t biespecífica de psma e cd3 de engate de construtos de anticorpos
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US11262359B2
(en)
|
2016-02-05 |
2022-03-01 |
NanoView Biosciences, Inc. |
Detection of exosomes having surface markers
|
SG10202007025PA
(en)
|
2016-03-14 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
AU2017300788B2
(en)
|
2016-07-22 |
2023-11-16 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
CN115925780A
(zh)
|
2016-07-22 |
2023-04-07 |
美国安进公司 |
含有Fc的蛋白的纯化方法
|
EP3490600A1
(en)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
BR112019004214A2
(pt)
|
2016-09-06 |
2019-05-28 |
Dana Farber Cancer Inst Inc |
métodos para tratar ou prevenir infecção pelo vírus zika
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
AU2017339858B2
(en)
|
2016-10-03 |
2022-02-17 |
Abbott Laboratories |
Improved methods of assessing GFAP status in patient samples
|
JP2020503256A
(ja)
|
2016-11-04 |
2020-01-30 |
ノビミューン エスアー |
抗cd19抗体およびそれを使用する方法
|
WO2018090052A1
(en)
|
2016-11-14 |
2018-05-17 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
KR102533814B1
(ko)
|
2016-11-28 |
2023-05-19 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
US11773182B2
(en)
|
2017-01-05 |
2023-10-03 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
AU2018240938A1
(en)
|
2017-03-24 |
2019-10-10 |
Zenyaku Kogyo Co., Ltd. |
Anti-IgM/B cell surface antigen bispecific antibody
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
JOP20190243A1
(ar)
|
2017-04-12 |
2019-10-13 |
Medimmune Llc |
علاج الربو بجسم مضاد لـ tslp
|
EP3610268A1
(en)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
US20200109390A1
(en)
|
2017-04-27 |
2020-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Coagulation factor ix with improved pharmacokinetics
|
BR112019022476A2
(pt)
|
2017-04-28 |
2020-05-12 |
Abbott Laboratories |
Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
JP7325936B2
(ja)
|
2017-05-05 |
2023-08-15 |
アムジエン・インコーポレーテツド |
改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AU2018272311A1
(en)
|
2017-05-26 |
2019-12-19 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
WO2018222784A1
(en)
|
2017-05-30 |
2018-12-06 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
EA201992502A1
(ru)
|
2017-06-20 |
2020-04-22 |
Эмджен Инк. |
Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
JP7160491B2
(ja)
|
2017-07-14 |
2022-10-25 |
ファイザー インコーポレイティッド |
MAdCAMに対する抗体
|
MX2020001327A
(es)
|
2017-08-04 |
2020-03-20 |
Amgen Inc |
Metodo de conjugacion de cys-acm.
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
WO2019107384A1
(ja)
|
2017-11-28 |
2019-06-06 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
AU2018375719A1
(en)
|
2017-11-29 |
2020-05-28 |
Board Of Regents Of The University Of Texas System |
Compositions and methods for cancer therapy
|
EP3721233A2
(en)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
WO2019112860A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
AU2018383679A1
(en)
|
2017-12-11 |
2020-05-07 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
AU2019207812A1
(en)
|
2018-01-12 |
2020-07-23 |
Bristol-Myers Squibb Company |
Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
|
AR114080A1
(es)
|
2018-01-12 |
2020-07-22 |
Amgen Inc |
Anticuerpos pac1 y sus usos
|
US20210363238A1
(en)
|
2018-01-31 |
2021-11-25 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
EP3765499A1
(en)
|
2018-03-12 |
2021-01-20 |
Zoetis Services LLC |
Anti-ngf antibodies and methods thereof
|
US11203646B2
(en)
|
2018-03-14 |
2021-12-21 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
JPWO2019225568A1
(ja)
|
2018-05-21 |
2021-07-01 |
中外製薬株式会社 |
ガラス容器に封入された凍結乾燥製剤
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
CN108707599A
(zh)
*
|
2018-05-31 |
2018-10-26 |
东北农业大学 |
一种小鼠胚胎干细胞单细胞融合方法
|
EP3803332A1
(en)
|
2018-06-01 |
2021-04-14 |
NanoView Biosciences, Inc. |
Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
|
AU2019301336B2
(en)
|
2018-07-10 |
2022-11-24 |
Mitsubishi Tanabe Pharma Corporation |
Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
|
AU2019313444A1
(en)
|
2018-07-30 |
2021-02-18 |
Amgen Inc. |
Prolonged administration of a bispecific antibody construct binding to CD33 and CD3
|
TWI830761B
(zh)
|
2018-08-03 |
2024-02-01 |
德商安美基研究(慕尼黑)公司 |
針對cldn18.2和cd3之抗體構建體
|
MX2021002332A
(es)
|
2018-08-27 |
2021-08-11 |
Affimed Gmbh |
Células nk crioreservadas precargadas con una construcción de anticuerpo.
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
US20220125754A1
(en)
|
2019-01-29 |
2022-04-28 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
US20220113313A1
(en)
|
2019-02-01 |
2022-04-14 |
NanoView Biosciences, Inc. |
Systems and methods for vesicle cargo labeling and detection
|
AU2020218446B2
(en)
|
2019-02-04 |
2023-05-25 |
National University Corporation Ehime University |
"CAR LIBRARY AND scFv MANUFACTURING METHOD
|
CA3130103A1
(en)
|
2019-02-13 |
2020-08-20 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
US20220098290A1
(en)
|
2019-02-28 |
2022-03-31 |
Juntendo Educational Foundation |
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
|
WO2020189748A1
(ja)
|
2019-03-19 |
2020-09-24 |
中外製薬株式会社 |
Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
CA3136398A1
(en)
|
2019-04-10 |
2020-10-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying fc region-modified antibody
|
US20220204608A1
(en)
|
2019-04-17 |
2022-06-30 |
Hiroshima University |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
CA3141690A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
JPWO2020246563A1
(no)
|
2019-06-05 |
2020-12-10 |
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
AU2020304671A1
(en)
|
2019-06-28 |
2022-01-20 |
Amgen Inc. |
Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
|
US20220281966A1
(en)
|
2019-07-26 |
2022-09-08 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
CA3152946A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
US20210147525A1
(en)
|
2019-10-18 |
2021-05-20 |
The Regents Of The University Of California |
Methods and compositions for treating pathogenic blood vessel disorders
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
JPWO2021145435A1
(no)
|
2020-01-15 |
2021-07-22 |
|
|
CN114980929A
(zh)
|
2020-01-15 |
2022-08-30 |
国立大学法人大阪大学 |
糖尿病性自主神经障碍的预防或治疗剂
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy for npm1c-positive cancer
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
WO2021193928A1
(ja)
|
2020-03-27 |
2021-09-30 |
株式会社PhotoQ3 |
腫瘍細胞を死滅させるための医薬
|
JPWO2021206078A1
(no)
|
2020-04-06 |
2021-10-14 |
|
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
JPWO2021235537A1
(no)
|
2020-05-22 |
2021-11-25 |
|
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
IL299103A
(en)
|
2020-06-18 |
2023-02-01 |
Regeneron Pharma |
Formulations of activin A antibody and methods of its use
|
WO2021261546A1
(ja)
|
2020-06-24 |
2021-12-30 |
国立大学法人 東京大学 |
光増感色素
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
US20230322867A1
(en)
|
2020-07-24 |
2023-10-12 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
MX2023000854A
(es)
|
2020-07-28 |
2023-02-15 |
Chugai Pharmaceutical Co Ltd |
Formulacion de jeringa precargada con aguja con protector de aguja que contiene nuevo anticuerpo modificado.
|
MX2023001120A
(es)
|
2020-07-31 |
2023-02-22 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
JP2023538897A
(ja)
|
2020-08-20 |
2023-09-12 |
アムジエン・インコーポレーテツド |
Fab領域中に非標準的なジスルフィドを有する抗原結合タンパク質
|
US20240092890A1
(en)
|
2020-08-27 |
2024-03-21 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
WO2022076474A2
(en)
|
2020-10-07 |
2022-04-14 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
BR112023008670A2
(pt)
|
2020-11-06 |
2024-02-06 |
Amgen Inc |
Construtos polipeptídicos ligados à cd3
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced cleavage rate
|
BR112023008629A2
(pt)
|
2020-11-06 |
2023-10-03 |
Amgen Inc |
Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
TW202302143A
(zh)
|
2021-03-12 |
2023-01-16 |
日商中外製藥股份有限公司 |
重症肌無力症之治療或預防用之醫藥組合物
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
EP4314065A1
(en)
|
2021-03-22 |
2024-02-07 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
AU2022263406A1
(en)
|
2021-04-20 |
2023-10-19 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CN117999098A
(zh)
|
2021-09-24 |
2024-05-07 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
JPWO2023058723A1
(no)
|
2021-10-08 |
2023-04-13 |
|
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
CA3237090A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|